|
Vaccine Detail
Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo |
Vaccine Information |
- Vaccine Name: Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007226
- Type: DNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- GM-CSF (human)
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Adjuvant:
- Description: An allogeneic cancer vaccine composed of lethally irradiated, whole pancreatic cancer cells transfected with a plasmid carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Allogeneic GM-CSF-secreting tumor vaccine PANC 6.03 pcDNA-1/GM-Neo secretes GM-CSF thereby activating dendritic cells, promoting antigen presentation to B- and T-cells, and promoting a cytotoxic T-lymphocyte (CTL) response. This may eventually kill tumor cells. The pancreatic tumor cells are derived from the PANC 6.03 tumor cell line. (NCIT_C101891).
Allogenic pancreatic tumor cell vaccine transfected with the granulocyte macrophage colony-stimulating factor (GM-CSF) gene alone or given in combination with either a single intravenous dose or daily metronomic oral doses of cyclophosphamide has been used for the treatment of patients with surgically resected adenocarcinoma of the head, neck, tail or the uncinate process of the pancreas. NCT01088789
|
Host Response |
|
References |
NCIT_C101891: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C101891]
|
|